Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

NCT05777993 is registered in ClinicalTrials.gov with Agios Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05777993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05777993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Lead sponsor
Agios Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
July 6, 2023
Completion date
August 31, 2029
Enrollment
59 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, hemolytic, pyruvate kinase deficiency, sickle cell disease, thalassemia